Week 8 is decision day. You have eight weeks of substrate to read: calprotectin, hs-CRP, zonulin if you ran it, IL-6, and the symptom log you've kept since Day 1. The protocol doesn't change because you feel like changing it. It changes because the labs tell you which of three biological scenarios you're actually in — and each scenario has a different next move.
The mistake at Week 8 is treating the protocol as monolithic. It isn't. Phase 1 (BPC-157 oral + KPV) is a mucosal repair signal. Phase 2 (TB-500 + GHK-Cu) is a connective-tissue and quality-control layer. The Week 8 labs are telling you whether the mucosal signal landed, whether the inflammatory cascade actually quieted, and whether the gut barrier itself is rebuilding — or whether something upstream is still feeding the fire. Practitioner consensus across high-volume peptide practices is consistent: pain resolution precedes tissue remodeling, and symptom improvement precedes marker normalization. The labs are the lagging-but-honest indicator. Trust them over how you feel.
The mechanism of "response" — what each marker is actually telling you
Calprotectin is neutrophil-derived. When it falls, neutrophil infiltration of the gut mucosa is resolving — the immune cells that were chewing on your epithelium have gone home. This is the cleanest single marker of mucosal healing in IBD-spectrum and leaky-gut presentations. The corpus tracks calprotectin specifically with KPV because KPV addresses intestinal inflammation directly at the mucosal layer.
hs-CRP is hepatic, downstream of IL-6. It's a systemic inflammation reading — it tells you whether the gut-derived inflammatory signal is still reaching the rest of your body. NF-kB activation, elevated CRP, and the TNF-alpha / IL-6 / IL-1beta cascade are the upstream drivers the Phase 1 stack is built to suppress. If CRP is falling but calprotectin isn't, you've quieted the systemic noise but the local mucosa is still inflamed. If calprotectin is falling but CRP isn't, something else is driving systemic inflammation — and your gut isn't the only fire.
Zonulin (if tracked) is tight-junction permeability. Oral BPC-157 was discovered in gastric juice; it targets the GI tract directly, repairing tight junctions, reducing mucosal inflammation, and restoring gut barrier integrity. Falling zonulin = the barrier is sealing. This is the marker that closes the loop on "leaky gut."
Three patterns emerge at Week 8. Each one has a defined next protocol.
Branch A — Clear response
Definition: Calprotectin down 40%+ from baseline. hs-CRP down to near-normal range. Symptom log shows resolution of the cardinal complaints (bloating, urgency, post-meal cramping). Zonulin trending toward normal if tracked.
You executed Phase 1 and Phase 2 correctly, and the gut responded. The temptation here is to stop. Don't stop when symptoms stop. Practitioner consensus across the corpus on every mucosal protocol — including the analogous orthopedic protocols where pain resolution precedes tissue remodeling — is the same: stopping at symptom resolution leaves structural healing incomplete. Tight junctions are sealed but not yet reinforced. The new collagen TB-500 laid down through Week 5-10 needs finishing time.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| BPC-157 | 500 mcg/day | Oral | Daily, Weeks 9-12 | Expert 🟢 | Continue at maintenance dose. Mucosal finishing. |
| GHK-Cu | 200 mcg/day | SubQ | Daily, Weeks 9-12 | Expert 🟢 | Quality-control phase. Tissue finishing. Mirrors the post-op Week 5-8 transition pattern. |
| KPV | Taper | Oral | Drop to every other day Weeks 9-10, then stop | Expert 🟢 | Inflammatory signal is quiet — taper, don't cliff-edge. |
| TB-500 | Discontinue | — | — | — | Loading and remodeling phases complete. |
Retest calprotectin and hs-CRP at Week 12. If both are in the normal range, transition to Chapter 10 maintenance.
Branch B — Partial response
Definition: Calprotectin down but still elevated above the upper reference (e.g. started at 250 µg/g, now at 120 µg/g, normal <50). hs-CRP improving but not normal. Symptoms 50-70% better — real progress, incomplete resolution. This is the most common pattern.
Two things are happening biologically: the Phase 1+2 stack is working, but either (a) there is a residual driver upstream the protocol hasn't fully addressed, or (b) the mucosa needs more time at therapeutic dose. The corpus treats partial response as a signal to escalate intelligently — add a mitochondrial or systemic layer, don't just extend the same stack at the same dose.
The relevant escalation pattern from the corpus: when Phase 1 of the mitochondrial work is partial, the response is to add BPC-157 (500 mcg/day) to accelerate mitochondrial membrane repair, retest CRP, and only then re-evaluate. Mirror that logic here — extend the foundation, then add a leverage point.
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| BPC-157 | 500 mcg twice daily | Oral | Daily, Weeks 9-14 | Expert 🟢 | Escalate to BID. Mucosal repair signal not yet saturated. |
| KPV | 500 mcg | Oral or SubQ | Daily, Weeks 9-14 | Expert 🟢 | Hold dose. Calprotectin still elevated = neutrophil signal still active. |
| TB-500 | 2.5 mg | SubQ | Every 5 days, Weeks 9-12 | Expert 🟢 | Maintenance from the loading phase — connective tissue layer is not finished. |
| MOTS-c | 5-10 mg/week (split 2x weekly) | SubQ | Weeks 11-14 | Expert 🟢 | Add the mitochondrial layer. Gut epithelial cells are among the highest-turnover ATP-demanding cells in the body. If mitochondrial output is the rate-limiter on epithelial regeneration, MOTS-c addresses it. Activates AMPK; stimulates mitochondrial biogenesis. |
| GHK-Cu | 200 mcg/day | SubQ | Daily, Weeks 9-14 | Expert 🟢 | Continue. Anti-inflammatory and tissue remodeling layer. |
Retest at Week 14. The corpus is explicit: do not retry an escalation layer if the baseline isn't holding — energy, tolerance, no adverse reactions are prerequisites for adding MOTS-c. If fatigue worsens on MOTS-c, pull it and stay on the extended Phase 1+2.
Branch C — No response
Definition: Calprotectin unchanged or worse. hs-CRP flat or rising. Symptoms unchanged. You did the protocol; the gut didn't move.
This is not a peptide-failure scenario. This is a diagnostic gap scenario. Practitioner consensus is unambiguous: when a fundamentally sound mucosal protocol produces zero movement over 8 weeks, you are not treating the actual driver. The substrate calls out three high-probability upstream drivers that no peptide stack can outrun:
- Active SIBO/SIFO. Until you eradicate the bacterial or fungal overgrowth, BPC-157 and KPV are repairing a wall while the termites are still active. The corpus is direct on this: "Quick-fix diets may help short term, but often miss deeper root causes like impaired motility, poor digestion, or stress. Until you correct the underlying imbalance, the cycle continues." Pair an elimination diet with targeted antimicrobial eradication (rifaximin for SIBO-H/D; antifungals like fluconazole for SIFO). The peptide stack resumes after eradication.
- CIRS / biotoxin illness. If you have water-damaged-building exposure history, the inflammatory driver is not gut-resident. Shoemaker panel: TGF-beta 1, C4a, MSH, VIP, MMP-9, VEGF, visual contrast sensitivity. VIP is the gold-standard intervention for CIRS resolution — gut-directed peptides will not move this.
- Food antigen / autoimmune driver still active. Ongoing exposure to a triggering antigen keeps NF-kB activation, CRP, and the TNF-alpha / IL-6 / IL-1beta cascade switched on. Until the antigen is removed, mucosal repair can't outpace mucosal damage.
| Action | What to do | Why |
|---|---|---|
| Pause peptide escalation | Hold Phase 1+2 at maintenance dose only | Don't stack more peptides on an undiagnosed driver |
| Run SIBO breath test | Lactulose breath test (hydrogen + methane) | Rule in/out the most common silent driver |
| Run Shoemaker panel (if exposure history) | TGF-beta 1, C4a, MSH, VIP, MMP-9 | Rule in/out CIRS |
| Stool panel with stool calprotectin + zonulin + pathogen PCR | Comprehensive stool analysis | Find the organism or marker the basic labs missed |
| Resume peptide protocol after driver is identified | Return to Chapter 3 Phase 1 stack | The protocol works when it's pointed at the right target |
What you should feel by Week 12 (post-adjustment)
- Branch A: Symptoms remain resolved. Energy stable or improving. New labs confirm the trajectory.
- Branch B: Continued incremental gain — another 20-30% symptom reduction. Calprotectin should drop into normal or near-normal range. If MOTS-c was tolerated, expect a noticeable energy lift by Week 11-12.
- Branch C: No expected change from peptides until the upstream driver is addressed. The "feel" milestone is diagnostic clarity, not symptom improvement.
What's NOT happening yet
- Calprotectin does not normalize the day you finish Phase 2. It lags symptom improvement by weeks. A still-elevated calprotectin at Week 8 is not protocol failure — it's the marker doing its job as a lagging indicator.
- Adding more peptides does not fix a no-response scenario. Stacking more compounds on an undiagnosed SIBO or CIRS driver burns budget and produces no movement. The corpus is consistent on this — when the foundation isn't responding, escalate diagnostics, not dose.
- MOTS-c is not a Phase 2 gut layer by default. It earns its place in Branch B specifically when mitochondrial-limited epithelial regeneration is the suspected rate-limiter. It is not added because "more is better."
- Symptom resolution is not the endpoint. Tight junctions seal weeks before the lab confirms it; remodeling completes weeks after. Stopping at "I feel fine" is the most common reason gut protocols recur within six months.
Research describes these branch points. Read the labs, pick the branch, and adjust.